Statera Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	2021	2020	2019	2018
Period Ending	Sep '22 Sep 30, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Net Income	-91.83	-101.85	-12.09	-3.22	-6.13
Depreciation & Amortization	0.56	0.26	0	-	-
Asset Writedown & Restructuring Costs	67.6	67.6	-	-	-
Stock-Based Compensation	0.5	6.36	2.7	1.87	5.22
Other Operating Activities	-2.68	-1.62	4.36	-	-
Change in Accounts Receivable	-0.87	-0.42	-	-	-0.05
Change in Accounts Payable	9.1	1	0.28	0.69	-2.9
Change in Unearned Revenue	0.39	0.24	-	-	-
Change in Other Net Operating Assets	5.58	0.66	-0.33	0.42	-0.42
Operating Cash Flow	-12.09	-28.19	-5.08	-0.24	-4.27
Capital Expenditures	-0.1	-0.18	-0.01	-	-
Cash Acquisitions	0	13.65	-	-	-
Investing Cash Flow	-0.1	13.46	-0.01	-	-
Short-Term Debt Issued	-	0.2	-	0.23	1.27
Long-Term Debt Issued	-	14.67	-	-	-
Total Debt Issued	0.5	14.87	-	0.23	1.27
Short-Term Debt Repaid	-	-0.9	-	-	-0.25
Total Debt Repaid	-10.1	-0.9	-	-	-0.25
Net Debt Issued (Repaid)	-9.6	13.97	-	0.23	1.02
Issuance of Common Stock	8.01	7.34	1.35	-	3.26
Other Financing Activities	-	-0.33	-0.06	-	-
Financing Cash Flow	-1.6	20.99	5.68	0.23	4.27
Foreign Exchange Rate Adjustments	0.08	-0.01	-	-	-
Net Cash Flow	-13.71	6.25	0.59	-0.01	0.01
Free Cash Flow	-12.19	-28.38	-5.09	-0.24	-4.27
Free Cash Flow Margin	-330.68%	-1908.24%	-	-	-
Free Cash Flow Per Share	-0.25	-0.81	-0.70	-0.01	-0.25
Cash Interest Paid	1.51	1.25	-	-	-
Levered Free Cash Flow	0.34	-10.13	-3.82	2.28	-
Unlevered Free Cash Flow	1.39	-9.32	-3.74	2.36	-
Change in Net Working Capital	-11.77	-1.88	0.05	-1.11	-

Source: S&P Capital IQ. Standard template. Financial Sources.